RCMNY
TXMD icon

Rubric Capital Management (New York)’s TherapeuticsMD TXMD Stock Holding History

Rubric Capital Management (New York)’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63M Hold
1,192,191
– – 0.02% 84
2026
Q1 		$2.41M Hold
1,192,191
– – 0.03% 81
2025
Q4 		$1.94M Hold
1,192,191
– – 0.02% 73
2025
Q3 		$1.28M Hold
1,192,191
– – 0.01% 72
2025
Q2 		$1.38M Hold
1,192,191
– – 0.02% 64
2025
Q1 		$1.1M Hold
1,192,191
– – 0.02% 65
2024
Q4 		$1.03M Hold
1,192,191
– – 0.01% 68
2024
Q3 		$1.98M Hold
1,192,191
– – 0.03% 61
2024
Q2 		$1.92M Hold
1,192,191
– – 0.05% 65
2024
Q1 		$2.73M Hold
1,192,191
– – 0.08% 65
2023
Q4 		$2.68M Hold
1,192,191
– – 0.06% 55
2023
Q3 		$3.6M Hold
1,192,191
– – 0.14% 58
2023
Q2 		$4.91M Hold
1,192,191
– – 0.21% 55
2023
Q1 		$4.47M Sell
1,192,191
-565,000
-32% -$2.71M 0.12% 63
2022
Q4 		$9.82M Buy
1,757,191
+600,238
+52% +$3.53M 0.43% 56
2022
Q3 		$7.68M Buy
1,156,953
+365,122
+46% +$2.96M 0.39% 54
2022
Q2 		$7.88M Buy
791,831
+684,945
+641% +$6.54M 0.41% 49
2022
Q1 		$2.03M Hold
106,886
– – 0.07% 69
2021
Q4 		$1.9M Hold
106,886
– – 0.09% 63
2021
Q3 		$3.96M Buy
106,886
+51,000
+91% +$2.26M 0.11% 52
2021
Q2 		$3.33M Hold
55,886
– – 0.21% 52
2021
Q1 		$3.74M Sell
55,886
-34,526
-38% -$2.7M 0.22% 57
2020
Q4 		$5.47M Sell
90,412
-188,239
-68% -$12.9M 0.4% 51
2020
Q3 		$22M Buy
278,651
+92,946
+50% +$7.41M 2.05% 22
2020
Q2 		$11.6M Sell
185,705
-6,532
-3% -$380K 1.34% 32
2020
Q1 		$10.2M Sell
192,237
-28,027
-13% -$2.78M 1.61% 24
2019
Q4 		$26.7M Buy
220,264
+82,653
+60% +$11.9M 3.01% 15
2019
Q3 		$25M Buy
137,611
+2,760
+2% +$389K 2.29% 16
2019
Q2 		$17.5M Buy
134,851
+41,032
+44% +$7.36M 1.38% 26
2019
Q1 		$22.8M Buy
93,819
+62,914
+204% +$16.6M 2.13% 22
2018
Q4 		$5.89M Buy
+30,905
New +$7.54M 0.73% 36

Other funds holding TXMD

CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Rubric Capital Management (New York)'s TXMD Position: Q2 2026 in Review

Rubric Capital Management (New York) held its TherapeuticsMD (TXMD) position steady in Q2 2026 at 1,192,191 shares worth $2.63M. The position accounts for 0.02% of the portfolio, ranked #84.

Rubric Capital Management (New York) first reported a position in TXMD in Q4 2018 and has held it in 31 quarters since. The position peaked at $26.7M in Q4 2019. 45 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Rubric Capital Management (New York) held 1,192,191 shares of TherapeuticsMD worth $2.63M as of Q2 2026.
  • Rubric Capital Management (New York) left its TherapeuticsMD share count unchanged in Q2 2026.
  • TherapeuticsMD made up 0.02% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #84 holding.
  • Rubric Capital Management (New York) first reported a position in TherapeuticsMD in Q4 2018 and has held it in 31 quarters since.
  • Rubric Capital Management (New York)'s TherapeuticsMD position peaked at $26.7M in Q4 2019.
  • 45 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.